MBX Biosciences, Inc. (MBX)
NasdaqGS
Price as at 30 Sept 2026, 21:06 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
MBX Biosciences, Inc. trades at $58.62. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Marshall Wace, MARSHALL WACE, LLP$22.18M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$12.48M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$10.09M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$6.26M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$1.25M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own MBX?
5 of the institutions we track reported a position in MBX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its MBX data?
Fundamentals for MBX come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:06 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for MBX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.